Five Prime Therapeutics, Inc. (FPRX): Price and Financial Metrics


Five Prime Therapeutics, Inc. (FPRX): $38.00

0.01 (+0.03%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add FPRX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

FPRX Stock Price Chart Interactive Chart >

Price chart for FPRX

FPRX Price/Volume Stats

Current price $38.00 52-week high $38.90
Prev. close $37.99 52-week low $2.61
Day low $37.95 Volume 1,006,600
Day high $38.01 Avg. volume 1,981,352
50-day MA $31.27 Dividend yield N/A
200-day MA $15.17 Market Cap 1.77B

Five Prime Therapeutics, Inc. (FPRX) Company Bio


Five Prime Therapeutics discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. The company was founded in 2001 and is based in South San Francisco, California.


FPRX Latest News Stream


Event/Time News Detail
Loading, please wait...

FPRX Latest Social Stream


Loading social stream, please wait...

View Full FPRX Social Stream

Latest FPRX News From Around the Web

Below are the latest news stories about Five Prime Therapeutics Inc that investors may wish to consider to help them evaluate FPRX as an investment opportunity.

Amgen Completes The Acquisition Of Five Prime Therapeutics

Amgen has completed the acquisition of the clinical-stage biotechnology company Five Prime Therapeutics. Amgen had previously announced a tender offer to buy all outstanding common stock at the price of $38.00 per share in cash. The aggregate payment that was to be made for the merger is $1.9B, excluding transaction expenses. Amgen is a biotech company that focuses on unlocking biological potential and innovations that cater to patients suffering from serious illnesses. Amgen (AMGN) focuses on unmet needs in the human therapeutics field, and Five Prime Therapeutics (FPRX) will add to its overall oncology portfolio.

Neha Gupta on TipRanks | April 20, 2021

Amgen Successfully Completes Acquisition Of Five Prime Therapeutics

Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Prime Therapeutics (NASDAQ:FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, for $38.00 per share in cash. The aggregate consideration to be paid by Amgen to complete the tender offer and the subsequent merger is approximately $1.9 billion without giving effect to related transaction fees and expenses.

Yahoo | April 16, 2021

SHAREHOLDER ALERT: WeissLaw LLP Reminds HWCC, FI, SVBI, and FRPX Shareholders About Its Ongoing Investigations

If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

Yahoo | April 1, 2021

Halper Sadeh LLP Investigates the Following Mergers - TPCO, STAY, KSU, CUB, AEGN, FPRX; Shareholders Are Encouraged to Contact the Firm

Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

Yahoo | March 30, 2021

Lifshitz Law Firm, P.C. Announces Investigation of FPRX, NBLX, PAND, and SHBI

NEW YORK, NY / ACCESSWIRE / March 21, 2021 / Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Lifshitz Law Firm, P.

Yahoo | March 21, 2021

Read More 'FPRX' Stories Here

FPRX Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year 546.26%
5-year 30.76%
YTD N/A
2021 0.00%
2020 270.59%
2019 -50.65%
2018 -57.57%
2017 -56.26%

Continue Researching FPRX

Here are a few links from around the web to help you further your research on Five Prime Therapeutics Inc's stock as an investment opportunity:

Five Prime Therapeutics Inc (FPRX) Stock Price | Nasdaq
Five Prime Therapeutics Inc (FPRX) Stock Quote, History and News - Yahoo Finance
Five Prime Therapeutics Inc (FPRX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.569 seconds.